AI assistant
Sending…
BIO-RAD LABORATORIES, INC. — Director's Dealing 2018
May 12, 2018
30786_dirs_2018-05-11_8e51a644-c0b9-47ed-bd77-56c17f898def.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIO RAD LABORATORIES INC (BIO, BIOB)
CIK: 0000012208
Period of Report: 2018-05-11
Reporting Person: SCHWARTZ NORMAN D (Director, Chairman, President and CEO, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-05-11 | Bio-Rad B Common Stock | M | 37500 | $88.48 | Acquired | 280418 | Direct |
| 2018-05-11 | Bio-Rad B Common Stock | F | 24273 | $284.98 | Disposed | 256145 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-05-11 | Non-Qualified Stock Option (right to buy) | $88.48 | M | 37500 | Disposed | 2018-06-11 | Bio-Rad B Common Stock (37500) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Bio-Rad A Common Stock | 411252 | Direct |
| Bio-Rad B Common Stock | 12717 | Indirect |
| Bio-Rad B Common Stock | 4060054 | Indirect |
Footnotes
F1: The reporting person disclaims beneficial ownership of these shares.
F2: The shares are held by a limited partnership of which the reporting person is a limited and general partner. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F3: The option vested in five equal annual installments beginning on June 11, 2009.
More from BIO-RAD LABORATORIES, INC.
Regulatory Filings
2026
May 13
Regulatory Filings
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Regulatory Filings
2026
Apr 24
Major Shareholding Notification
2026
Mar 26
Annual Report
2026
Mar 25
Proxy Solicitation & Information Statement
2026
Mar 25
Regulatory Filings
2026
Feb 19
Annual Report
2026
Feb 13